Advertisement
Advertisement
U.S. markets open in 8 hours 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ipsen S.A. (IPN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
94.90+1.35 (+1.44%)
At close: 05:35PM CEST
Advertisement

Ipsen S.A.

65 Quai Georges Gorse
Cedex
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees4,500

Key Executives

NameTitlePayExercisedYear Born
Mr. David LoewMD, CEO & Director2.3MN/A1967
Mr. Aymeric Le ChatelierExec. VP & Group CFON/AN/A1969
Dr. Aidan Murphy Ph.D.Exec. VP of Technical OperationsN/AN/A1966
Mr. Craig MarksVice-Pres of Investor RelationsN/AN/AN/A
Mr. Francois GarnierExec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics OfficerN/AN/A1962
Ms. Gwenan WhiteExec. VP of Communications & Public AffairsN/AN/AN/A
Mr. Regis MulotExec. VP & Chief HR OfficerN/AN/A1966
Mr. Stephan GagneHead of New Tokyo OfficeN/AN/AN/A
Ms. Dominique BeryHead of Nordics & BalticsN/AN/A1971
Dr. Yan Moore M.D.Sr. VP & Head of Oncology Therapeutic AreaN/AN/A1967
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Corporate Governance

Ipsen S.A.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement